Developer docs
API playgroundTry for free, no card

Search company profiles

Amethyst Radiotherapy

Full company profile

uuid0002b6s

Namestring
Amethyst Radiotherapy
Legal namestring
Amethyst Radiotherapy Group
Websiteurl
amethyst-radiotherapy.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Amethyst Radiotherapy Group (legal entity) operates a European network of radiotherapy clinics delivering advanced radiation therapy, radiosurgery, brachytherapy and chemotherapy services to cancer patients. Founded in 2010 and headquartered in the Netherlands (with its founding base in Compiègne, France), the company runs 15 specialist treatment centres across six countries — Austria, France, Italy, Poland, Romania and the United Kingdom — staffed by multidisciplinary clinical teams that tailor treatment plans to individual patients. Its technology stack centres on advanced radiotherapy modalities, and the group has publicly positioned AI-enabled radiotherapy planning as a tool to improve precision and expand treatment capacity, though no proprietary AI research or model disclosures are available.

Amethyst sits within the Stingray Healthcare Group, Europe's largest independent cancer care platform headquartered in Lausanne, Switzerland, which operates more than 30 centres across eight European countries and treats approximately 40,000 patients per year. Under a partnership-led model, Amethyst works with healthcare professionals and institutional partners — preserving clinical independence while modernising oncology infrastructure through long-term investment and technology upgrades. The group invests in equipment, clinical best-practice sharing and integration across centres, with acquired subsidiaries (e.g., Medical Equipment Solutions Ltd, 2020) supporting equipment lifecycle capabilities.

Revenue is generated through fee-for-service radiotherapy and oncology treatments, with pricing negotiated through national healthcare systems, insurance providers and government health programmes rather than published rate cards. Distribution is direct via owned treatment centres (a Direct Sales / field enterprise channel targeting health systems), supplemented by institutional referral partnerships and healthcare professional relationships. Capital structure has been progressively built through a 2015 Accession Capital Partners round (~€23.5M), a 2019 Rohatyn Group round, and a June 2024 €300M debt facility from Credit funds managed by Ares Management Corporation, primarily to fund further European expansion and radiotherapy technology investment.

Short descriptiontext

Amethyst Radiotherapy Group operates 15 specialist cancer treatment centres across six European countries, delivering radiotherapy, radiosurgery, brachytherapy and chemotherapy services to cancer patients within the Stingray Healthcare Group platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
external beam radiotherapy, radiosurgery services, brachytherapy treatment, radiotherapy clinics, oncology treatment centers
Industry5 codes
1Radiation Oncology
CodeHLAKAFACPrimaryYes
2Ambulatory Oncology Centers (Outpatient Chemo/Radiation)
CodeHLAFABAIPrimaryNo
3Oncology & Cancer Specialty Hospitals
CodeHLAFAHACPrimaryNo
4Medical Oncology
CodeHLAKAFABPrimaryNo
5Nuclear Medicine Clinical Services & Therapy Centers
CodeHLAIAGAIPrimaryNo
NAICS code2 codes
  • Ambulatory Health Care Services621
  • Specialty (except Psychiatric and Substance Abuse) Hospitals622310
SIC code3 codes
  • Services-Specialty Outpatient Facilities, Nec8093
  • Services-Health Services8000
  • Services-Offices & Clinics Of Doctors Of Medicine8011
Product category
Radiotherapy & Cancer Treatment Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Radiotherapy Treatment Services
TypeSubscription Recurring
Description

Amethyst generates revenue through providing radiotherapy and oncology treatment services across its network of treatment centers in Europe. Services include radiotherapy, radiosurgery, brachytherapy and chemotherapy treatments tailored to individual patients by multidisciplinary clinical teams.

amethyst-radiotherapy.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

Amethyst Radiotherapy Group operates a pan-European network of 15 specialized cancer treatment centers providing external beam radiotherapy, stereotactic radiosurgery (CyberKnife), brachytherapy, and chemotherapy. Services are delivered through partnerships with healthcare professionals and institutions across Austria, France, Italy, Poland, Romania, and the United Kingdom, with treatment plans tailored to individual oncology patients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Expanded access to high-quality oncology services across Europe
Product overview1 text field

Amethyst Radiotherapy operates as a radiotherapy operator offering a comprehensive suite of cancer treatment services. The company functions as a single-service offering (radiotherapy-centred oncology care) with treatment modalities including radiotherapy, radiosurgery, brachytherapy, and chemotherapy. These services are delivered across multiple specialist treatment centres in six European countries, with treatments tailored to individual patients by multidisciplinary clinical teams.

Product and service1 record
1External Beam Radiotherapy
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Stingray Healthcare Group
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Amethyst operates as part of the Stingray Healthcare Group network, Europe's largest independent cancer care platform. The partnership enables sharing of clinical best practices, innovation, and high-quality cancer care at scale across European radiotherapy centres.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Amethyst Radiotherapy

Radiotherapy & Cancer Treatment Servicesamethyst-radiotherapy.com

Amethyst Radiotherapy Group operates 15 specialist cancer treatment centres across six European countries, delivering radiotherapy, radiosurgery, brachytherapy and chemotherapy services to cancer patients within the Stingray Healthcare Group platform.

What Amethyst Radiotherapy does

Amethyst Radiotherapy Group (legal entity) operates a European network of radiotherapy clinics delivering advanced radiation therapy, radiosurgery, brachytherapy and chemotherapy services to cancer patients. Founded in 2010 and headquartered in the Netherlands (with its founding base in Compiègne, France), the company runs 15 specialist treatment centres across six countries — Austria, France, Italy, Poland, Romania and the United Kingdom — staffed by multidisciplinary clinical teams that tailor treatment plans to individual patients. Its technology stack centres on advanced radiotherapy modalities, and the group has publicly positioned AI-enabled radiotherapy planning as a tool to improve precision and expand treatment capacity, though no proprietary AI research or model disclosures are available.

Amethyst sits within the Stingray Healthcare Group, Europe's largest independent cancer care platform headquartered in Lausanne, Switzerland, which operates more than 30 centres across eight European countries and treats approximately 40,000 patients per year. Under a partnership-led model, Amethyst works with healthcare professionals and institutional partners — preserving clinical independence while modernising oncology infrastructure through long-term investment and technology upgrades. The group invests in equipment, clinical best-practice sharing and integration across centres, with acquired subsidiaries (e.g., Medical Equipment Solutions Ltd, 2020) supporting equipment lifecycle capabilities.

Revenue is generated through fee-for-service radiotherapy and oncology treatments, with pricing negotiated through national healthcare systems, insurance providers and government health programmes rather than published rate cards. Distribution is direct via owned treatment centres (a Direct Sales / field enterprise channel targeting health systems), supplemented by institutional referral partnerships and healthcare professional relationships. Capital structure has been progressively built through a 2015 Accession Capital Partners round (~€23.5M), a 2019 Rohatyn Group round, and a June 2024 €300M debt facility from Credit funds managed by Ares Management Corporation, primarily to fund further European expansion and radiotherapy technology investment.

Amethyst Radiotherapy firmographics

Firmographics
Name
Amethyst Radiotherapy
Legal name
Amethyst Radiotherapy Group
Website
https://amethyst-radiotherapy.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
Amethyst Radiotherapy Group operates 15 specialist cancer treatment centres across six European countries, delivering radiotherapy, radiosurgery, brachytherapy and chemotherapy services to cancer patients within the Stingray Healthcare Group platform.
Ownership category
akta.pro rank

Amethyst Radiotherapy industry classification

Industry
Product category
Radiotherapy & Cancer Treatment Services
NAICS
Ambulatory Health Care Services (621), Specialty (except Psychiatric and Substance Abuse) Hospitals (622310)
SIC
Services-Specialty Outpatient Facilities, Nec (8093), Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011)
akta.pro primary industry
Radiation Oncology (HLAKAFAC)
akta.pro secondary industries
Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Oncology & Cancer Specialty Hospitals (HLAFAHAC), Medical Oncology (HLAKAFAB), Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI)

Keywords

  • External beam radiotherapy
  • Radiosurgery services
  • Brachytherapy treatment
  • Radiotherapy clinics
  • Oncology treatment centers

Where Amethyst Radiotherapy is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices7 records

Markets served

Amethyst Radiotherapy business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain

Revenue model

  1. Radiotherapy Treatment Services: Amethyst generates revenue through providing radiotherapy and oncology treatment services across its network of treatment centers in Europe. Services include radiotherapy, radiosurgery, brachytherapy and chemotherapy treatments tailored to individual patients by multidisciplinary clinical teams.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Amethyst Radiotherapy product offering

Product offering

Core offering

Amethyst Radiotherapy Group operates a pan-European network of 15 specialized cancer treatment centers providing external beam radiotherapy, stereotactic radiosurgery (CyberKnife), brachytherapy, and chemotherapy. Services are delivered through partnerships with healthcare professionals and institutions across Austria, France, Italy, Poland, Romania, and the United Kingdom, with treatment plans tailored to individual oncology patients.

Product overview

Amethyst Radiotherapy operates as a radiotherapy operator offering a comprehensive suite of cancer treatment services. The company functions as a single-service offering (radiotherapy-centred oncology care) with treatment modalities including radiotherapy, radiosurgery, brachytherapy, and chemotherapy. These services are delivered across multiple specialist treatment centres in six European countries, with treatments tailored to individual patients by multidisciplinary clinical teams.

Differentiator

Problem solved

Functional benefit

Products and services

  • External Beam Radiotherapy

Quantifiable outcome

  • Expanded access to high-quality oncology services across Europe

Companies that use Amethyst Radiotherapy

Customer profile

Segments1 record

Ideal customer profiles2 records

Amethyst Radiotherapy technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Amethyst Radiotherapy partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Stingray Healthcare GroupcoreStrategic or Co-development PartnerAmethyst operates as part of the Stingray Healthcare Group network, Europe's largest independent cancer care platform. The partnership enables sharing of clinical best practices, innovation, and high-quality cancer care at scale across European radiotherapy centres.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Amethyst Radiotherapy competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key highlights6 records

Customer concentration

Amethyst Radiotherapy social profiles

Digital presence

Amethyst Radiotherapy financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Amethyst Radiotherapy leadership team

Management profile

Number of profiles

Profiles3 records

Amethyst Radiotherapy funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Amethyst Radiotherapy M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amethyst Radiotherapy

What does Amethyst Radiotherapy do?

Amethyst Radiotherapy Group operates a pan-European network of 15 specialized cancer treatment centers providing external beam radiotherapy, stereotactic radiosurgery (CyberKnife), brachytherapy, and chemotherapy. Services are delivered through partnerships with healthcare professionals and institutions across Austria, France, Italy, Poland, Romania, and the United Kingdom, with treatment plans tailored to individual oncology patients.

Is Amethyst Radiotherapy a public or private company?

Amethyst Radiotherapy is a private company. It is classified as private equity controlled and is currently operating.

When was Amethyst Radiotherapy founded?

Amethyst Radiotherapy was founded in 2014. It employs 51 to 100 people.

Where is Amethyst Radiotherapy based?

Amethyst Radiotherapy is headquartered in Paris, France, in the Europe region.

How does Amethyst Radiotherapy make money?

One revenue line is on record: radiotherapy Treatment Services.

Does Amethyst Radiotherapy have an API?

No public API is recorded for Amethyst Radiotherapy.

What industry is Amethyst Radiotherapy in?

Amethyst Radiotherapy's product category is Radiotherapy & Cancer Treatment Services. Its primary akta.pro industry code is HLAKAFAC, Radiation Oncology, with a secondary code of HLAFABAI, Ambulatory Oncology Centers (Outpatient Chemo/Radiation). Its NAICS code is 621 and its SIC code is 8093.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinSMEsAmethyst Radiotherapy Secures €300M in Financing from Ares ManagementAmethyst Radiotherapy Group secured a €300 million financing agreement from Credit funds managed by Ares Management Corporation. This investment is intended to accelerate Amethyst's expansion across Europe, where it currently operates 15 radiotherapy centres in six countries.Amethyst-RadiotherapyAmethyst Successfully Secureed €300m for EU Expansion PlansAmethyst Radiotherapy Group has secured a €300 million financing agreement with Credit funds managed by Ares Management Corporation to fuel its expansion across Europe. The investment will support the establishment of new treatment centres and the deployment of advanced radiotherapy technologies to address the growing demand for oncological services.InvestorsinhealthcareThe Netherlands: Amethyst Radiotherapy Secures €300m in financing from Ares ManagementAmethyst Radiotherapy, a Netherlands-based private operator of radiotherapy services, has secured a €300m financing agreement with Credit funds managed by Ares Management Corporation. This funding supports the expansion of Amethyst's linear accelerator technology and cancer treatment operations across Europe. The deal highlights continued investment in European healthcare infrastructure despite broader market conditions.GlobeNewswireAmethyst Radiotherapy orders Elekta cancer treatment solutions for European expansionElekta will deliver advanced radiotherapy equipment to Amethyst Radiotherapy, a private cancer network in Western and Central Europe, for approximately EUR 28 million. The order was booked in the second quarter of Elekta's fiscal year. Amethyst expects to have 20 clinics and 42 linear accelerators by 2020.